- Poster presentation
- Open Access
Succesful treatment of diffuse sclerosing osteomyelitis of the mandible/mandibular chronic non-bacterial osteitis with intravenous pamidronate: resolution of pain and radiographic bone inflammation with improved cosmetic appearance - a case study
© Miettunen et al; licensee BioMed Central Ltd. 2014
- Published: 17 September 2014
- Fibrous Dysplasia
- Visual Analogue Score
Diffuse sclerosing osteomyelitis of the manidble ( DSMO) is a form of chronic non-bacterial osteitis (CNO) and predominantly affects patients < 18 years. It can result in cosmetic disfigurement. No uniformly effective treatment exists. Intravenous pamidronate (IV-PAM) has been reported to be effective in multifocal CNO.
To describe clinical and radiologic outcome of a DSMO patient following treatment with IV-PAM.
A 4-year old Caucasian female was diagnosed with DSMO and prospectively followed from 2007-2014. She presented with a 20-month history of facial asymmetry and painful bony expansion of the left hemimandible. CT-scan revealed bone expansion suggestive of fibrous dysplasia, but two consecutive bone biopsies revealed inflammatory cells only. Infectious osteomyeltis was also suspected, but cultures were negative and IV and oral antibiotics were of no benefit. Focal MRI revealed bone marrow and soft tissue edema with periosteal reaction, consistent with DSMO. Subsequent whole-body MRI revealed no other bony lesions. Naproxen was of no benefit and she was started on monthly 1-day IV-PAM infusions (1st dose 0.5mg/kg; each subsequent dose: 1mg/kg). The response to treatment was assessed according to visual analogue score for pain ( VAS, 0=no pain; 10=maximum pain), sequential MRIs and clinical photos.
She received 8 monthly IV-PAM infusions. After 1st dose, VAS decreased from 10 to 0. MRI documented resolution of abnormal signal at 5 months with gradual mandibular remodelling. Clinical photos confirmed resolution of facial asymmeter over 5 years with sustained improvement at 7 years. She had a minor MRI confirmed flare at 67 months which responded to Naproxen monotherapy. She remains asymptomatic at 84 month follow-up.
DSMO is challenging to diagnose and treat due to its rareness and lack of uniformly effective treatment. IV-PAM was effective in this young refractory patient and resulted in resolution of pain, mandibular remodelling and cosmetic improvement.
P. Miettunen: grant / research support from: Novartis. A. Rice: none declared. X. C. Wei: none declared. W. Yu: none declared.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.